Background
==========

Through the efforts of many individuals in the past few years, it has become possible to genetically transform a wide variety of non-drosophilid insects of medical and agricultural importance \[[@B1]\]. The ability to genetically transform mosquito species allows researchers to better understand mechanisms of vector competence, design novel methods to disrupt vector-pathogen relationships and develop new insect control strategies \[[@B2]-[@B5]\]. New molecular methods could potentially augment continued traditional efforts to control malaria and other re-emerging arthropod-borne diseases. Similar approaches may also be used to stem the devastating infestation of economically important crops by insecticide-resistant pest strains.

Mosquitoes transmit to humans some of the most debilitating and deadly diseases known. According to the World Health Organization, malaria alone is responsible for one million deaths annually \[[@B6]\]. Additionally, the transmission of yellow fever, dengue fever, West Nile virus and a variety of other encephalitis viruses permanently disrupt or end untold numbers of lives. Both anopheline \[[@B7]-[@B10]\] and culicine \[[@B11]-[@B17]\] mosquito species have been successfully transformed. In all cases, the process is labor-intensive with a few successful experiments yielding transformation efficiencies ranging from 0.5% to 13%. These transformation efficiencies are low compared to the nearly 50% previously reported in *Drosophila*with vectors up to 8 kb in size \[[@B18]\]. Additionally, transgene expression in the yellow fever mosquito varies considerably both between and within families \[[@B11],[@B12],[@B19]\], likely due to differences in the transcriptional environments of specific insertion sites within the genome, such as the proximity of the transgene to enhancers or heterochromatic stretches of DNA. This phenomenon is of particular concern in the *Ae. aegypti*genome given its large size (\~780 Mb) and its apparent pattern of short-period interspersion where single copy genes (1 to 2 kb) alternate with short (200--600 bp) or medium (1--4 kb) length repetitive sequences \[[@B20]\]. The problem is complex, however transposition has been shown to be dependent upon the amount of transiently available transposase to catalyze vector integration \[[@B21],[@B22]\]. Also, the effective use of genetically-altered mosquitoes to augment current disease vector control requires the ability to create and maintain transgenic lines with consistent, predictable and high-level expression patterns of effector transgenes.

Looking to maximize the transcription of rare transgenes that do land in favorable environments and to potentially increase the levels of transiently available transposase, we tested the ability of three different enhancer elements; SV40 \[[@B23]\], *copia*ULR (*Drosophila*) \[[@B24]\] and Hr3 (*Bombyx mori*nuclear polyhedrosis virus or NPV) \[[@B25]\], to increase the levels of transcription from each of three heterologous promoters from the following genes: actin5C \[[@B26]\] and polyubiquitin (Ubi-p63E -- hereafter referred to as pUb) \[[@B27]\] from *Drosophila*and the intermediate early gene (IE1) \[[@B28]\] from the *Autographa californica*multicapsid nuclear polyhedrosis virus (MNPV). Additionally, we tested the ability of the *B. mori*baculovirus IE1 gene product \[[@B29]\], which binds to repetitive sequences within the baculovirus homologous regions (Hrs) \[[@B30],[@B31]\] and has previously been shown to function as a powerful *trans*activator in transfected lepidopteran cells \[[@B29]\], to yet further increase gene expression in mosquito cells.

Results
=======

The Hr3 enhancer and the IE1 transactivator increase reporter gene activity in transiently transfected C7-10 Aedes albopictus cells
-----------------------------------------------------------------------------------------------------------------------------------

In transiently transfected C7-10 cells, the Act5C promoter resulted in the highest luciferase reporter activity in comparison with the remaining promoters alone (Fig. [1A](#F1){ref-type="fig"}). The level of measured activity directly corresponds to the amount of luciferase protein expressed by the transfected cells and thus presumably the level of transcription. Among the enhancers, Hr3 improved luciferase expression by 4-fold, 47-fold and 22-fold over the basal level expression from the Act5C, IE1 and pUb promoters respectively; cULR improved luciferase expression over basal level from the Act5C, IE1 and pUb promoters 2-fold, 11-fold and 10-fold respectively; and eSV40 resulted in 2-fold, 8-fold and 7-fold increases respectively in luciferase expression from the Act5C, IE1 and pUb promoters (Fig. [1A](#F1){ref-type="fig"}). Addition of the IE1 *trans*activator unexpectedly resulted in large increases in expression from the *Renilla*control plasmid, as well as from the Hr3-containing reporter plasmids. This is seen in the apparent drop of expression indicated by the red-shaded bars in Fig. [1A](#F1){ref-type="fig"}. This was confirmed in several independent experiments and was seen even with decreased concentrations of the *Renilla*plasmid (see [additional file 1](#S1){ref-type="supplementary-material"}). In order to see the relative effect of the IE1 transactivator on expression from the Hr3/promoter constructs, the raw firefly luciferase values were converted to a % of average pSLIE1Luc expression and plotted on a log scale (Fig. [1B](#F1){ref-type="fig"}). Firefly luciferase expression increased 50--200-fold over the basal level expression of all of the promoters with the addition of the IE1 *trans*activator.

![Firefly luciferase expression from various promoter/enhancer plasmids in *Aedes albopictus*C7-10 cells. Cells were assayed for luciferase expression 24 hrs. post-transfection. The averages of five replications are reported and error is reported as +/- 1 standard error. (A) To normalize for differences in transfection efficiency and cell cycle state within the experiment, the firefly luciferase luminescence values for each construct were divided by the corresponding *Renilla*luciferase luminescence values measured in a dual luciferase assay. Bars in red indicate the presence of the IE1 *trans*activator. The Hr3 enhancer clearly outperforms both the cULR and the eSV40 enhancers in combination with each of the promoters. (B) Raw firefly luciferase values are reported as a % of pSLIE1Luc expression on a log scale. The bars in red show levels of firefly luciferase expression in the presence of the IE1 *trans*activator. Addition of the IE1 *trans*activating protein (Hr3+) increased firefly luciferase expression 2.5--4-fold over all Hr3-promoter combinations alone and 50--200-fold over basal promoter expression.](1471-2199-5-8-1){#F1}

IE1 transactivator interacts with promoter sequences in addition to the Hr3 enhancer
------------------------------------------------------------------------------------

Analysis of multiple experiments (Fig. [2](#F2){ref-type="fig"}, Table [1](#T1){ref-type="table"}, and data not shown) revealed an interesting trend regarding the effect of the IE1 *trans*activating protein upon the promoters themselves. This effect was different for each promoter when co-transfected with an identical plasmid expressing the *Renilla*luciferase control. Addition of the IE1 *trans*activator resulted in a 17-fold increase in expression of firefly luciferase from the Act5C promoter over its basal level expression and a concomitant 30-fold increase from the *Renilla*luciferase reporter under the control of the hsp82 promoter from *Drosophila pseudobscura*\[[@B32]\]. When the IE1 promoter was used to drive expression of firefly luciferase, expression increased 169-fold over the basal level expression, while *Renilla*luciferase expression from the hsp82 promoter increased 138-fold. Finally, firefly luciferase expression increased 11-fold relative to basal level expression from the pUb promoter with a corresponding 202-fold increase in *Renilla*luciferase expression from the hsp82 promoter.

![Differential effect of the IE1 *trans*activator on the transcription levels from various promoters. Each promoter-Luc construct was co-transfected with phsp82*Renilla*Luc, both in the absence and presence of the IE1 *trans*activator, and assayed for both firefly and *Renilla*luciferase expression, 24 hrs. post-transfection. One experiment with six replicates was performed with the same batch of cells, DNA/liposome complexes and luciferase reagents. Error is reported as +/- 1 standard error. Each set of data is plotted both on a linear and a log scale. (A) Addition of the *trans*activator (+) caused a 16-fold increase in firefly luciferase expression from the Act5C promoter, a 169-fold increase in expression from the IE1 promoter and an 11-fold increase in expression from the pUb promoter. (B) The same data as shown in (A) but plotted on a log scale. (C) Addition of the *trans*activator resulted in different levels of expression from the phsp82*Renilla*Luc construct depending upon which promoter was used to drive expression of the firefly luciferase construct. (D) The same data as shown in (C) but plotted on a log scale.](1471-2199-5-8-2){#F2}

###### 

Change in Basal Luciferase Expression from Promoters with Addition of the IE1 *Trans*activator

  **Promoter**   **Firefly Luciferase**   ***Renilla*Luciferase**   **Ratio**
  -------------- ------------------------ ------------------------- -----------
  **Act5C**      ↑ 17 x                   ↑ 30 x                    ↓ 1.9 x
  **IE1**        ↑ 169 x                  ↑ 138 x                   ↑ 1.2 x
  **pUb**        ↑ 11 x                   ↑ 202 x                   ↓ 18.3 x

This summary of the data presented in Fig. 2 shows the fold change of firefly luciferase expression from each basal promoter following addition of the IE1 *trans*activator, the fold-increase in expression from the control *Renilla*luciferase plasmid under control of the hsp82 promoter and the overall change in ratio.

Discussion
==========

Unexpectedly, the internal control for transfection and protein recovery, *Renilla*luciferase, could not reliably be used as such in the presence of the *trans*activator. The data presented reveal a differential effect of the IE1 *trans*activator (Fig. [2](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}) that profoundly affects expression levels from the two luciferase plasmids in an enhancer/promoter-dependent manner. This compromises the ability to compare expression values both within an experiment where IE1 is present in some samples but not in others and between experiments where different batches of cells and assay reagents are employed. The results of a single experiment involving the *trans*activator are reported here, however additional experiments show similar results. The ratio of firefly to *Renilla*luciferase is reported for all promoter/enhancer combinations to allow accurate comparison of the three promoters alone and in combination with each of the three enhancers. It should be noted that the addition of the transactivator does significantly increase firefly luciferase expression from all three promoters with the Hr3 enhancer sequence, though this is masked by the simultaneous increase in expression from the *Renilla*luciferase control plasmid.

The IE1 *trans*activator is clearly interacting with the promoters in *trans*, even in the absence of the Hr3 enhancer element (Fig. [2](#F2){ref-type="fig"}, Table [1](#T1){ref-type="table"} and data not shown). This observation agrees with previously published data that the cytoplasmic A3 actin gene promoter of *B. mori*was upregulated as much as one hundred-fold by the co-transfection of a plasmid encoding the *B. mori*IE1 gene product (BmIE1) \[[@B29]\]. When the Hr3 enhancer is present, there is a cooperative effect, and luciferase expression increases as much as 200-fold (Fig. [1](#F1){ref-type="fig"}) over that of the promoter alone. This cooperativity is consistent with results obtained with Hr3-enhanced CAT expression cassettes driven by the *B. mori*cytoplasmic actin gene promoter co-expressed with the BmIE1 protein in lepidopteran cell lines *Bm5*and *Sf*21 (an increase of up to three orders of magnitude) \[[@B29]\].

The significant differences seen in expression from each of the promoters tested (Fig. [2](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}) reveal that not all promoters are affected in the same manner, nor is the co-transfected plasmid. The presence of the Hr3 enhancer region upstream of the promoter driving expression of the IE1 *trans*activator protein, results in high levels of IE1 protein from a relatively low amount of plasmid DNA. Despite this abundance of IE1 protein, it appears that transcription from the pUb promoter, in the absence of the Hr3 enhancer, increases only 11-fold (Fig. [2A](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}), while transcription from the hsp82 promoter driving *Renilla*luciferase expression is exceptionally high (Fig. [2B](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}). The simplest explanation is that the IE1 protein has different affinities for binding sites on the various promoters and/or the IE1 protein is sequestering necessary basal transcription factors. It has also been observed that some viral promoters, IE-0, IE-2 and PE-38, are inhibited by IE1 expression \[[@B33]-[@B35]\]. Clearly, the actions of the IE1 *trans*activator in this study are consistent with its ability to bind Hrs \[[@B36]-[@B38]\]. In addition, the protein has two independent functional acidic activation domains and two potential positively-charged inhibitory domains \[[@B39],[@B40]\], consistent with its observed ability to both enhance and inhibit expression from different promoters. Also, lower concentrations of the plasmid bearing the IE1 gene sequence in these transient assays result in greater increases in luciferase expression (see [additional file 2](#S2){ref-type="supplementary-material"}). This observation is consistent with the mechanism of negative regulation by the IE1 protein previously proposed \[[@B35]\] where the cooperative binding of the Hrs occurs at a lower concentration than that required for binding to the half sequence regions (Hs) present in negatively regulated promoters. It is also consistent with the presence of the Hr3 enhancer sequence on the plasmid producing the IE1 *trans*activating protein, which results in up-regulation of IE1 transcription, consequently reducing the number of plasmid copies needed to produce optimal protein levels. When this experiment was repeated using pUb to drive *Renilla*luciferase expression (data not shown and [additional file 3](#S3){ref-type="supplementary-material"}), significant differences between promoters were also observed, though not the same differences described above with the hsp82-*Renilla*expression plasmid. Finally, it should be noted that each of the enhancers alone also differentially affected the expression from each promoter. These data collectively highlight the value of evaluating the effects of new promoter/enhancer/*trans*activator combinations on the expression of a reporter gene within a related cell line, prior to investing significant time and effort in the creation of transgenic lines. Though cell lines do not completely mimic the cellular and nuclear environment of an entire organism, they can yield significant insight into both the potential interaction between regulatory elements driving transgene expression and the potential impact of unknown endogenous *trans*acting factors.

Conclusions
===========

Clearly, we have shown that the baculovirus homologous region, Hr3, along with the IE1 *trans*activating protein, significantly increases transgene expression from each of the three heterologous, constitutive promoters tested in mosquito cells. Some concern does exist that endogenous promoters might be down-regulated by the presence of the IE1 protein, and that available host cell transcription factors might be sequestered by complexes stabilized by the IE1 *trans*activator, however a lower concentration of IE1 *trans*activator would likely mitigate these effects. Preliminary transposition assays confirm the ability of the Hr3 enhancer/IE1 *trans*activator combination to function in syncytial preblastoderm mosquito embryos and to significantly increase observed transposition frequencies when used to drive transposase expression (Coates, *et al*., unpublished data). Use of tissue-specific promoters/enhancers and/or inducible expression may effectively reduce any potential fitness load imposed by interactions of the ie1 protein with endogenous regulatory elements. Perhaps the most promising application is the use of HR/IE1 in helper plasmids transiently expressing transposase in an attempt to increase the number of stable transgene integration events by increasing the amount of available transposase, particularly if germline-specific promoters were used to express the *trans*activator protein. The HR/IE1 strategy is a promising tool for high-level transgene expression and/or increased transposition frequency in culicine mosquitoes and possibly other insect species as well.

Methods
=======

Construction of the luciferase expression plasmids
--------------------------------------------------

A 2.7-kb *Hind*III-*Sal*I fragment from pGL2-Basic (Promega), containing the firefly luciferase coding region and the SV40 poly-Adenylation signal, was inserted into the corresponding sites of pBCKS+ (Stratagene) to create pBCLuc. A 2.7-kb *Sma*I-*Sal*I fragment from pBCLuc was inserted into the *Sma*I-*Sal*I sites of pSL*fa*1180*fa*(\[[@B41]\] to create pSLLuc. The *Drosophila*Actin5C promoter was excised from pHermesA5CEGFP \[[@B13]\] by *Pst*I and *Bam*HI digestion and inserted into the corresponding sites of PSLLuc to create PSLAct5CLuc. The *Sac*II site was removed from pIE1-3 (Novagen) and then the 657-bp *Eco*RI-*Bam*HI fragment containing the AcMNPV IE1 promoter was inserted into the corresponding sites of pSLLuc to create pSLIE1Luc. A 2-kb *Kpn*I-*Bam*HI fragment from pB \[pUB-nls-EGFP\] \[[@B42]\] containing the *Drosophila*polyubiquitin promoter was inserted into the corresponding sites of pSLLuc to create pSLpUbLuc. The *copia*ULR was amplified by polymerase chain reaction (PCR) from *copia*LTR-ULR-CAT \[[@B43]\] using the primers 5\'-AAGCTTGGGCCCAGTCCATGCCTA-3\' and 5\'-CCGCGGATTACGTTTAGCCTTGTC-3\', cleaved by digestion with *Hind*III and *Sac*II and inserted into the corresponding sites of pBCKS+ to create pBCcULR. The *Hind*III-*Sac*II fragment from this plasmid was then inserted into the corresponding sites of pSLAct5CLuc and pSLIE1Luc to create pSLcULRAct5CLuc and pSLcULRIE1Luc. pBCcULR was digested with *Hind*III and the site filled with the Klenow fragment of DNA polymerase I (Promega), then digested with *Sac*II and ligated into pSLpUbLuc which had been cut with *Not*I and the site filled with Klenow fragment, then cut with *Sac*II to create pSLcULRpUbLuc. The SV40 enhancer region from pRL-SV40 (Promega) was PCR-amplified using the primers 5\'-AAGCTTCTGAGGCGGAAAGAACCA-3\' and 5\'-CCGCGGAAAATTAGCCAGCCATGG-3\', digested with *Hind*III and *Sac*II and inserted into the corresponding sites of pBCKS+ to make pBCeSV40. The *Hind*III-*Sac*II fragment of pBCeSV40 was then inserted into the corresponding sites of pSLAct5CLuc and pSLIE1Luc to create pSLeSV40Act5CLuc and pSLeSV40IE1Luc. pBCeSV40 was digested with *Hind*III, the site filled with Klenow fragment, then digested with *Sac*II and ligated to pSLpUbLuc digested with *Not*I, the site filled with Klenow fragment and subsequently digested with *Sac*II to produce pSLeSV40pUbLuc. A 1.2-kb *Pst*I-*Bam*HI fragment containing the *B. mori*NPV Hr3 enhancer from p153 \[[@B25]\] was inserted into the corresponding sites of pBCKS+ to create pBCHr3. The *Pst*I-*Bam*HI fragment of pBCHr3 was inserted into the corresponding sites of pSLAct5CLuc to create pSLHr3Act5CLuc. The *Hind*III-*Sac*II fragment of pBCHr3 was inserted into the corresponding sites of pSLIE1Luc to create pSLHr3IE1Luc. The *Eco*RV-*Sac*II fragment of pBCHr3 was ligated to pSLpUbLuc digested with *Not*I, the site filled with Klenow fragment, and then digested with *Sac*II to create pSLHr3pUbLuc. phsp82*Renilla*Luc was created by inserting a 1-kb *Kpn*I-*Bam*HI fragment from pKhsp82 \[[@B44]\] into the corresponding sites of pBCKS+ and then inserting the *Kpn*I-*Pst*I fragment from this plasmid into the corresponding sites of pRL-SV40. ppUb*Renilla*Luc was created by first digesting pSLpUbLuc with *Not*I, filling in the site with Klenow fragment, then digesting with *Pst*I to produce a2-kb fragment which was ligated to pRL-SV40 prepared by digestion with *Bgl*II, the site filled with Klenow fragment and then digested with *Pst*I.

Cell cultures and transfections
-------------------------------

*Aedes albopictus*C7-10 cells were maintained at 25°C with 5% CO~2~in Eagle\'s media plus 5% fetal calf serum with the following additions per liter: 10 mL 10% (wt/vol) D(+)glucose, 10 mL 200 mM L-glutamine, 10 mL MEM vitamin solution, 20 mL MEM non-essential amino acids, 10 mL Penicillin/Streptomycin (10,000 U/mL), 29.3 mL sodium bicarbonate (7.5% w/v) \[[@B45]\]. 400 μL of cells at a density of 2 × 10^-6^cells/mL were seeded into 24-well microtiter plates and incubated at 25°C for 24 hrs. Cells were transfected with 0.4 μg total DNA and 0.8 μL LipofectAMINE 2000 (Life Technologies) in 10 μL serum-free, antibiotic-free media. phsp82*Renilla*Luc and the firefly constructs were transfected at a 1:2 ratio. The IE1 transactivator plasmid \[[@B25]\] was present as 1/10 of the total DNA.

Luciferase assays
-----------------

Transfected cells were assayed 24 hrs. post-transfection using a Turner Designs 20/20 luminometer and a Dual Luciferase Assay (Promega). The manufacturer\'s passive lysis protocol was followed. In addition, cell lysates were snap frozen in liquid nitrogen immediately after lysis to minimize luciferase protein degradation. All samples were diluted 20-fold in 1 × PLB (passive lysis buffer) in order to obtain a reading within the range of the luminometer.
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###### Additional File 1

The IE1 *trans*activator significantly affects expression from the *Renilla*luciferase control plasmid. Cells were transfected as detailed in the methods with 0.27 μg Hr3Act5CLuc (firefly) plasmid, 0.04 μg IE1 *trans*activator plasmid and the indicated amount of *Renilla*luciferase control plasmid. Because this is a control plasmid with no Hr3 enhancer element present, one would expect the expression levels to parallel those shown in the absence of the IE1 *trans*activator (solid bars).

###### 

Click here for file

###### Additional File 2

Lower concentrations of the IE1 *trans*activator result in greater expression from both the Hr3Actin5C (firefly luciferase) and the hsp82 (*Renilla*luciferase) promoters. Cells were transfected as detailed in the methods with 0.27 μg Hr3Act5CLuc (firefly) plasmid, 0.14 μg hsp82*Renilla*Luc plasmid and the indicated amount of IE1 *trans*activator plasmid.

###### 

Click here for file

###### Additional File 3

The hsp82 versus the pUb promoter for *Renilla*luciferase expression. Cells were transfected as detailed in the methods with the only difference being the promoter used to drive expression of the *Renilla*luciferase control plasmid. The pUb promoter seems to be upregulated more than the hsp82 promoter in the presence of the *trans*activator. Interestingly, the corresponding expression from the Hr3Act5C firefly luciferase plasmid is less when the pUb *Renilla*plasmid is co-transfected. Other differences were seen when this experiment was repeated with Hr3IE1 and Hr3pUb firefly luciferase plasmids. Clearly, the IE1 *trans*activator binds sequences other than the Hr3 enhancer sequence in eukaryotic promoters and the effect is dependent upon the combination of promoters present.

###### 

Click here for file
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